- Home
- ASLN
as 07-26-2024 4:00pm EST
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company's major business is research and development and operates only in one single segment.
| Founded: | 2010 | Country: | Singapore |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.1M | IPO Year: | 2018 |
| Target Price: | $90.67 | AVG Volume (30 days): | 285.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $20.08 | Next Earning Date: | 08-09-2024 |
| Revenue: | $12,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ASLAN Pharmaceuticals Limited News
ASLN Breaking Stock News: Dive into ASLN Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Sector Update: Health Care Stocks Higher Wednesday Afternoon
MT Newswires
9 days ago
Top Midday Decliners
MT Newswires
9 days ago
Aslan Pharmaceuticals Decides to File for Voluntary Liquidation; Shares Plunge
MT Newswires
10 days ago
Top Premarket Decliners
GlobeNewswire
10 days ago
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
MT Newswires
11 days ago
Sector Update: Health Care Stocks Edge Lower Late Afternoon
MT Newswires
11 days ago
Top Midday Decliners
MT Newswires
11 days ago
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Compare ASLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASLN ASLAN Pharmaceuticals Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.